aminolevulinic acid and Cheilitis

aminolevulinic acid has been researched along with Cheilitis in 23 studies

Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.

Cheilitis: Inflammation of the lips. It is of various etiologies and degrees of pathology.

Research

Studies (23)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Average Change in Local Skin Reactions to Blue Light Treatment

Assessments of swelling, erythema, and flaking/scaling were conducted after each treatment and two days post-treatment using a five-point ordinal scale (0: none to 4: severe). The average change in swelling, erythema and flaking/scaling after each treatment and two days post treatment were divided by the 50 total treatments to obtain the average value. (NCT02409732)
Timeframe: Baseline to Week 36

Average Change in Participant Reported Pain

Subject reported pain before, during and after blue light illumination was documented using a Visual Analogue Scale (VAS) from 0 (no pain) to 10 (worst pain imaginable). The maximum change in pain is 10 for each occurrence (pain before compared to during treatment and pain during compared to after treatment). This is multiplied by the number of subjects and then divided by the number of treatments to generate the range. The summation of the change between subject reported pain prior to compared to during blue light treatment was divided by the total number of treatments to obtain the average value. The summation of the change between subject reported pain during compared to after blue light treatment was divided by the total number of treatments to obtain the average value. (NCT02409732)
Timeframe: Baseline to Week 36

Number of Participants With a Change in Clearance From Baseline

Clearance will be estimated clinically as minimal (0%-25%), mild (26%-50%), moderate (51%-75%), good (76%-99%), or complete (100%). Results will also be evaluated by comparing photographs before and immediately after treatments, and 12 and 24 weeks after the last treatment. (NCT02409732)
Timeframe: Visit 2 (Baseline) to Visit 5 or 6 (Week 24 or 36)

Number of Participants With Adverse Events

Evaluation of any reported local or systemic events outside the treatment area and other than those specified under local skin reactions or PDT reactions. (NCT02409732)
Timeframe: Baseline to Week 36

The Number of Participants Who Developed a Local Skin Reaction to Blue Light Treatment: Vesiculation/Pustulation, Erosion/Ulceration, Crusting and Hyperpigmentation

Assessments of vesiculation/pustulation, erosion/ulceration, and crusting were conducted immediately after each blue light treatment using a five-point ordinal scale (0: none to 4: severe). The presence or absence of hyperpigmentation in the treatment area was also documented after each treatment visit. The total number of participants who developed a local skin reaction is documented. (NCT02409732)
Timeframe: Baseline to Week 36

Reviews

6 reviews available for aminolevulinic acid and Cheilitis

Trials

5 trials available for aminolevulinic acid and Cheilitis

Other Studies

12 other studies available for aminolevulinic acid and Cheilitis